Ardelyx is trading 10.16% higher at $3.34 after its November 3 report; a report linked the after-hours gain to strong demand and reaffirmed outlook. - Net loss was $0.7 million, effectively breakeven per share. - IBSRELA revenue rose 23% year over year to $96.3 million; revenue was $127.7 million, with estimates varying and the beat/miss unclear. - Ardelyx reaffirmed 2026 product revenue guidance and its 2027 profitability target; previous close was $3.03, and pre-market volume was not provided.